Overview: Serotonin Serum TestIntroduction: The Serotonin Serum Test measures serotonin to diagnose carcinoid syndrome, causing flushing or diarrhea. Aligned with 2023 NANETS guidelines, it uses biochemical methods for high specificity, supporting metabolic screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in biochemistry for patients with suspected carcinoid syndrome.
Other Names: Serum Serotonin Assay, 5-HT Blood Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: Serotonin testing began in the 1950s with carcinoid research. Biochemical methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures serotonin to diagnose carcinoid syndrome, guides treatment, and evaluates patients with flushing or diarrhea.
Test Parameters: 1. Serotonin Level
Pretest Condition: Fasting for 10-12 hours required. Collect serum or plasma. Report history of flushing, diarrhea, or carcinoid symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document flushing, diarrhea, or history of carcinoid tumors. Include current medications, especially SSRIs.
Consent: Written consent required, detailing the tests purpose, carcinoid syndrome implications, and risks of sample collection.
Procedural Considerations: Uses high-performance liquid chromatography (HPLC) to measure serotonin levels. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for carcinoid syndrome diagnosis.
Factors Affecting Result Accuracy: Improper fasting or sample hemolysis can affect results. Medications like SSRIs may elevate serotonin levels.
Clinical Significance: Elevated serotonin confirms carcinoid syndrome, guiding octreotide therapy or surgery. Normal levels may require urine serotonin testing.
Specialist Consultation: Consult an oncologist or endocrinologist for result interpretation and treatment planning.
Additional Supporting Tests: Urine 5-HIAA, chromogranin A, or imaging to confirm carcinoid syndrome diagnosis.
Test Limitations: Non-specific for certain neuroendocrine tumors; clinical correlation is needed. Sample quality affects sensitivity.
References: NANETS Carcinoid Guidelines, 2023; Journal of Clinical Oncology, Kulke MH, 2022.
